<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03742297</url>
  </required_header>
  <id_info>
    <org_study_id>GEM2017FIT</org_study_id>
    <nct_id>NCT03742297</nct_id>
  </id_info>
  <brief_title>Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years</brief_title>
  <official_title>Induction Therapy With Bortezomib-melphalan and Prednisone (VMP) Followed by Lenalidomide and Dexamethasone (Rd) Versus Carfilzomib, Lenalidomide and Dexamethasone (KRd) Plus/Minus Daratumumab, 18 Cycles, Followed by Consolidation and Maintenance Therapy With Lenalidomide and Daratumumab: Phase III, Multicenter, Randomized Trial for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PETHEMA Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PETHEMA Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed as a randomized, controlled, open-label, assessor blind, multicenter
      superiority trial with three parallel groups, and primary endpoint of immunophenotypic
      complete responses at 18 months after randomization. Block randomization will be performed
      with a 1:1:1 allocation ratio.

      Patients will be randomized up front to 3 arms. Patients will receive &quot;standard&quot; PETHEMA arm
      for fit elderly VMP x 9 + Rd x 9 (arm 1, control arm), a KRd regimen (arm 2a) (18 cycles) or
      a Carfilzomib-lenalidomida-dexametasona regimen combined with DARATUMUMAB (arm 2b) (18
      cycles).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After 18 cycles, patients not having received daratumumab before (arm 1 and 2a), will receive
      consolidation with 4 cycles of Lenalidomida-dexamethasone at low dose-DARATUMUMAB.

      At this point (after 22 months on treatment for the VMP-Rd and KRd arm and after 18 months of
      the Carfilzomib-lenalidomida-dexametasona-DARATUMUMAB arm) patients will be stratified
      according MRD status by flow and in both MRD- and MRD+ groups, patients will be randomized
      with a 1:1 allocation ratio to:

        1. no further treatment or

        2. continuous treatment with DARATUMUMAB-R (daratumumab plus lenalidomide up to 2 years and
           then lenalidomide continuous until progression).

      Patients on no maintenance that show biological relapse will be rechallenged with
      DARATUMUMAB-R.

      The translational part will be very robust with dysplasia monitoring (especially relevant for
      the Bortezomib-melfalán-prednisona + Lenalidomida-dexamethasone at low dose arm), clonal
      evolution/resistance follow up and immune reconstitution longitudinal follow up alongside
      with MRD status (at diagnosis, 9 months, 18 months, 22 months and treatment discontinuation).

      The trial is designed as a two-stage study (induction, followed by consolidation and
      maintenance). The first stage is confirmatory and addresses the primary efficacy objective.
      The second stage is exploratory and addresses the secondary efficacy and safety objectives.

      In the first stage, investigators will compare an optimized standard induction Bortezomib,
      talidomida and prednisone followed by Rd (18 cycles) versus KRd, that will be tested in this
      trial with or without daratumumab x 18 cycles. The main objective in this stage will be to
      compare the immunophenotypic complete response rate assessed by next generation flow at the
      end of induction.

      The second stage is exploratory and includes the consolidation and maintenance phases. In
      this second stage, the main objectives are:

        1. To compare the above mentioned induction strategies in terms of PFS at the end of the
           different treatment phases (induction, consolidation and maintenance).

        2. To investigate the capacity of consolidation with daratumumab-lenalidomide to reduce MRD
           levels in patients treated in the control arm as well as those that received KRd without
           daratumumab. In addition we will explore if this short consolidation can abrogate the
           potential benefit of a prolonged induction with KRd+daratumumab

        3. To explore the value of maintenance therapy according to MRD status (positive or
           negative) to prolong PFS (after a second randomization to receive or not maintenance
           therapy with lenalidomide and daratumumab) In order to prevent a potential treatment
           deficiency for patients randomized to &quot;no-maintenance&quot; in both MRD+ and MRD- subgroups,
           they will be offered to be re-challenged with lenalidomide-daratumumab as soon as they
           have a biological progression and have been censored for PFS. Moreover, if 30% of the
           patients randomized to &quot;no-maintenance&quot; relapse or progress during the first year, the
           protocol will be amended so that all patients receive maintenance therapy.

      Investigators consider that the here proposed multidrug sequential &quot;intensive&quot; approach
      designed to obtain the best possible and most durable response, assessed through the kinetics
      of MRD clearance, may have an impact in establishing future clinical practice in fit elderly
      patients. Moreover, in addition to the MRD analysis (based on next generation flow (NGF), NGS
      and CT-PET) comprehensive biological investigations, including immunoprofile, clonal
      selection, analysis of dysplastic features and circulating tumor cells, are planned in order
      to better understand the relationship between patients outcome and myeloma biology.

      The overall treatment plan has been designed for NDMM patients not candidates to SCT
      strategies but fit enough to tolerate a relatively intensive therapeutic strategy. According
      to the International Myeloma Working Group guidelines as well as the results obtained in our
      GEM2010 trial for elderly patients, we have decided to restrict this trial to fit elderly
      patients aged between 65 and 80 years because in our experience patients older than 80 years
      usually intensive treatments are poorly tolerated [1].

      Investigators will evaluate the frailty using a comprehensive health status assessment scale
      (Geriatric Assessment in Hematology, GAH scale, annex 11), already validated in patients with
      hematological diseases and preliminary results in multiple myeloma patients
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2018</start_date>
  <completion_date type="Anticipated">October 22, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 22, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy in terms of numbers of compleat responses</measure>
    <time_frame>18 months</time_frame>
    <description>Rate of immunophenotypic complete responses at 18 months, of the standard treatment in Spain for newly diagnosed multiple myeloma patients not candidates to stem cell transplantation,</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Newly Diagnosed Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>VMP x 9 + Lenalidomida-dexamethasone x 9</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bortezomib-melfalán-prednisone. Melfalán: 9mg/m2D1-4. Prednisone: 60mg/m2D1-4. Bortezomib: 1.3mg/m2 One 6 week cycleD1, 4, 8, 11, 22, 25, 29 and 32; followed by eight4-week cycleD1, 8, 15 and 22 Lenalidomida-dexametasona at low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carfilzomib-lenalidomida-dexamethasone regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>carfilzomib: 1 st cycle: 20mg/m2 day 1 and 36 mg/m2 days 2, 8, 9 &amp; 15, 16. 2nd cycle: 36 mg/m2 days 1, 2, 8, 9 &amp; 15, 16. Cycles 3-18: 56 mg/m2 days 1, 8 &amp; 15.Lenalidomida: 25 mg, d1-21 Dexamethasone : 40 mg, d1, 8, 15, 2218 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carfilzomib-lenalidomida-dexamethason with daratumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carfilzomib: 1 st cycle: 20mg/m2 day 1 and 36 mg/m2 days 2, 8, 9 &amp; 15, 16. 2nd cycle: 36 mg/m2 days 1, 2, 8, 9 &amp; 15, 16. Cycles 3-18: 56 mg/m2 days 1, 8 &amp; 15. Lenalidomida: 25 mg, d1-21 Dexamethasone: 40 mg, d1, 8, 15, 22 Daratumumab 16 mg/Kg IV Days 1, 8, 15, 22 of cycles 1-2; Days 1 and 15 of cycles 3 and 4; Day 1 of cycles 5 to 18</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide.</intervention_name>
    <description>Lenalidomide</description>
    <arm_group_label>Carfilzomib-lenalidomida-dexamethason with daratumumab</arm_group_label>
    <arm_group_label>Carfilzomib-lenalidomida-dexamethasone regimen</arm_group_label>
    <arm_group_label>VMP x 9 + Lenalidomida-dexamethasone x 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>Carfilzomib</description>
    <arm_group_label>Carfilzomib-lenalidomida-dexamethason with daratumumab</arm_group_label>
    <arm_group_label>Carfilzomib-lenalidomida-dexamethasone regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Bortezomib</description>
    <arm_group_label>VMP x 9 + Lenalidomida-dexamethasone x 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>Daratumumab</description>
    <arm_group_label>Carfilzomib-lenalidomida-dexamethason with daratumumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone</description>
    <arm_group_label>Carfilzomib-lenalidomida-dexamethason with daratumumab</arm_group_label>
    <arm_group_label>Carfilzomib-lenalidomida-dexamethasone regimen</arm_group_label>
    <arm_group_label>VMP x 9 + Lenalidomida-dexamethasone x 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone</description>
    <arm_group_label>VMP x 9 + Lenalidomida-dexamethasone x 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Melphalan</description>
    <arm_group_label>VMP x 9 + Lenalidomida-dexamethasone x 9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed multiple myeloma patients who require start active treatment according
             to the IMWG published in 2014

          -  Age between 65 and 80 years, both included

          -  Fit patient assessed using the comprehensive health status assessment scale (Geriatric
             Assessment in Hematology, GAH scale, annex 11) (0-94 points GAH scale). Patients with
             a punctuation ≤42 will be included.

          -  Signed informed consent

          -  Patients must have measurable disease, defined as follows:

        For secretory Multiple Myeloma, measurable disease is defined as the presence of
        quantifiable monoclonal component, ≥ 0.5 g/dL or, the urine light chains excretion is 200
        mg/24h or higher.

        For poor secretory or non secretory Multiple Myeloma, the level of the affected serum free
        light chain must be ≥ 10 mg/dL (≥ 100 mg/L, with an abnormal free light-chain ratio)

          -  Eastern Cooperative Oncology Group (ECOG) Performance status ≤2

          -  Life expectancy more than 3 months

          -  Adequate organ functions:

        Platelet count ≥ 50000/mm3, hemoglobin ≥ 8 g/dl and absolute neutrophil count ≥ 1000/mm3.
        Lower values are allowed only if they are due to BM infiltration.

        Aspartate Transaminase (AST) and Alanine Transaminase (ALT) ≤ 2.5 x Upper Limit of Normal.

        Total bilirubin: ≤2 x Upper Limit of Normal. Serum creatinine ≤ 2 mg/dl. Calcium ≤14mg/dl
        or corrected serum calcium ≤14mg/dl in patients whose albumin level is out of range Left
        ventricle ejection fraction ≥ 40%

          -  At the discretion of the investigator patient must be able to adhere to all study
             requirements.

          -  Male patients that receives lenalidomide should commit to use of a condom while taking
             the study drug every time he has sexual contact with a pregnant female of female of
             childbearing potential even if he has undergone a successful vasectomy; or practice
             complete abstinence (when this is the preferred and usual lifestyle of the subject);
             including during periods of dose interruptions and for at least 30 days after
             treatment completion. Also males under lenalidomide should commit not to donate semen
             or sperm during study drug treatment, including during periods of dose interruptions,
             and for at least 90 days after treatment completion.

        NOTE: Given the age of patients to be included on this Clinical Trial (between 65 and 80
        years, both included), there is no possibility of Females of Childbearing Potential (FCBP),
        therefore the Pregnancy Prevention Program (annex 12) has been modified accordingly.

        Exclusion Criteria:

          -  Patients older than 81 years or younger than 65

          -  Patients that do not qualify for fit according to the GAH scale (annex 11) (&gt;43 points
             GAH scale)

          -  Patients who have previously received treatment for multiple myeloma, except for
             steroid pulses in case of emergency, the administration of bisphosphonates or
             antialgesic radiotherapy or due to the presence of plasmacytomas requiring some
             emergency.

          -  Men who does not agree to use a condom every time he has sexual contact with a
             pregnant female or female of childbearing potential, even if he has undergone a
             successful vasectomy, or men who does not agree to practice complete abstinence (if
             this is the preferred and usual lifestyle of the subject).

          -  Left ventricular ejection fraction &lt;40% Prior history of malignancies, other than
             multiple myeloma (except for basal or squamous cell carcinoma of the skin, carcinoma
             in situ of the cervix or the breast), unless the patient has been free of the disease
             for ≥ 5 years.

          -  Other relevant diseases or adverse clinical conditions:

        Myocardial infarction within the 6 months prior to inclusion in the clinical trial A NYHA
        functional class III-IV, heart failure, uncontrolled angina, uncontrolled ventricular
        arrhythmia or acute ischemia detected electrocardiographically or conduction system
        anomalies.

        History of significant neurological or psychiatric disorders. Active infection. Significant
        non-neoplastic liver disease (e.g., cirrhosis, active chronic hepatitis).

        Poorly controlled arterial hypertension. Any serious medical condition or psychiatric
        illness that would interfere in understanding of the informed consent form.

          -  Human immunodeficiency virus (HIV) positive, hepatitis B surface antigen-positive or
             active hepatitis C infection

          -  Limitation of the patient's ability to comply with the treatment or follow-up
             protocol.

          -  Uncontrolled endocrine diseases (i.e. diabetes mellitus, hypothyroidism or
             hyperthyroidism) (i.e. requiring relevant changes in medication within the last month,
             or hospital admission within the last 3 months).

          -  Patients having a peripheral neuropathy ≥ Grade 2 within the 14 days prior to
             inclusion.

          -  Known hypersensibility to any of the study drugs or their excipients.

          -  Patients treated with any investigational drug during the previous 30 days.

          -  Patients with acute diffuse infiltrative pulmonary disease and/or pericardial disease.

          -  Patients who are unable or unwilling to undergo antithrombotic therapy.

          -  Patients with severe chronic obstructive pulmonary disease (COPD) or asthma with
             forced expiratory volume in the first minute (FEVI) less than 50%.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesús F San Miguel</last_name>
    <role>Study Chair</role>
    <affiliation>Clínica Universidad de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joan Blade, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Jose Lahuerta, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital 12 de Octubre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>M Victoria Mateos, Dr</last_name>
    <phone>+34923 29 11 00</phone>
    <email>mvmateos@usal.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana María Vale López, Dr</last_name>
      <phone>981 176654</phone>
      <email>Ana.MA.Vale.Lopez@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Albacete</name>
      <address>
        <city>Albacete</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ángela Martínez Hellín, Dr</last_name>
      <phone>976 597799</phone>
      <email>angelamartinezhellin@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascual Fernández Abellán, Dr</last_name>
      <phone>965 140268</phone>
      <email>fernandez_pas@gva.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol (ICO Badalona)</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert Oriol Rocafiguera</last_name>
      <phone>93 4978987</phone>
      <email>aoriol@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Rosiñol, Dr</last_name>
      <phone>93 2275400</phone>
      <email>LROSINOL@clinic.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Granell Gorrochategui, Dr</last_name>
      <phone>93 5565647</phone>
      <email>MGranell@santpau.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d´Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mercedes Gironella Mesa, Dr</last_name>
      <phone>93 2746100</phone>
      <email>mgironel@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO L´Hospitalet</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Sureda Balari, Dr</last_name>
      <phone>93 2607750</phone>
      <email>asureda@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Cruces</name>
      <address>
        <city>Bilbao</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Amutio Díez, Dr</last_name>
      <phone>946 006320</phone>
      <email>mariaelena.amutiodiez@osakidetza.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General de Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Belén Hernández Ruiz, Dr</last_name>
      <phone>926 278000</phone>
      <email>mbhernandez@sescam.jccm.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Cáceres</name>
      <address>
        <city>Cáceres</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Cabrera Silva, Dr</last_name>
      <phone>927 256200</phone>
      <email>ccabrerasilva1@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Regional Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Ángel Álvarez Rivas, Dr</last_name>
      <phone>957 010309</phone>
      <email>mangel.alvarez.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Cabueñes</name>
      <address>
        <city>Gijón</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mª Esther González García, Dr</last_name>
      <phone>985 185000</phone>
      <email>esthergongar@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Dr. Josep Trueta (ICO Girona)</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yolanda González Montes, Dr</last_name>
      <phone>972 225833</phone>
      <email>ygonzalez@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rafael Ríos Tamayo</last_name>
      <phone>958 020000</phone>
      <email>rafael.rios.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Especialidades de Jerez de la Frontera</name>
      <address>
        <city>Jerez De La Frontera</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastián Garzón López, Dr</last_name>
      <phone>956 032100</phone>
      <email>sebastianf.garzon.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Gran Canaria Dr. Negrín</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexia Suárez Cabrera, Dr</last_name>
      <phone>928 450486</phone>
      <email>asuacab@gobiernodecanarias.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de León</name>
      <address>
        <city>León</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Escalante Barrigón, Dr</last_name>
      <phone>987 237400</phone>
      <email>fescalanteb@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova de Lleida</name>
      <address>
        <city>Lleida</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio García Guiñón, Dr</last_name>
      <phone>973 705351</phone>
      <email>agarciag.lleida.ics@gencat.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro</name>
      <address>
        <city>Logroño</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josefa Nájera Irazu, Dr</last_name>
      <phone>941 298000</phone>
      <email>mjnajera@riojasalud.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Lucus Augusti</name>
      <address>
        <city>Lugo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esperanza Lavilla Rubia, Dr</last_name>
      <phone>982 296000</phone>
      <email>Esperanza.Lavilla.Rubira@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de octubre</name>
      <address>
        <city>MAdrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Jose Lahuerta, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rafael Martínez Martínez, Dr</last_name>
      <phone>91 3303321</phone>
      <email>rafaelbenigno.martinez@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mª Jesús Blanchard Rodríguez, Dr</last_name>
      <phone>91 3368053</phone>
      <email>mjesusblanchard@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan José Lahuerta Palacios, Dr</last_name>
      <phone>91 3908000</phone>
      <email>jjlahuerta@telefonica.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Fuenlabrada</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Flores Cornejo, Dr</last_name>
      <phone>91 6006379</phone>
      <email>rafael.flores@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrián Alegre Amor, Dr</last_name>
      <phone>91 5202316</phone>
      <email>adrian.alegre@telefonica.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Prieto Pareja, Dr</last_name>
      <phone>91 5504800</phone>
      <email>EPrieto@fjd.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Ángel Hernández Rivas, Dr</last_name>
      <phone>91 1918932</phone>
      <email>jahernandezr@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana López de la Guía, Dr</last_name>
      <phone>91 7277116</phone>
      <email>lopguia@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Madrid Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Pérez de Oteyza, Dr</last_name>
      <phone>91 7567863</phone>
      <email>jperezoteyza@hmhospitales.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital San Joan de Deu (Althaia)</name>
      <address>
        <city>Manresa</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Cabezudo, Dr</last_name>
      <phone>620992400</phone>
      <email>mcabezudo@althaia.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentin Cabañas Perianes, Dr</last_name>
      <phone>968 369532</phone>
      <email>valentin.cabanas@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Santa Lucía</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Romera Martínez, Dr</last_name>
      <phone>968 128600</phone>
      <email>marta.paramita@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Costa del Sol</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Casanova Espinosa, Dr</last_name>
      <phone>951 976798</phone>
      <email>mariacasanova@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricarda García, Dr</last_name>
      <phone>951 032000</phone>
      <email>ricarda_g@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Ourense</name>
      <address>
        <city>Ourense</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Angel Méndez Sánchez, Dr</last_name>
      <phone>988 3885500</phone>
      <email>Jose.Angel.Mendez.Sanchez@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ángel Ramírez Payer, Dr</last_name>
      <phone>985 108000</phone>
      <email>apayer.angel@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial de Palencia</name>
      <address>
        <city>Palencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Mª Alonso, Dr</last_name>
      <phone>979 167000</phone>
      <email>jalonsoa@saludcastillayleon.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llatzer</name>
      <address>
        <city>Palma De Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Bargay Lleonart, Dr</last_name>
      <phone>871 202000</phone>
      <email>jbargay@hsll.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonia Sampol Mayol, Dr</last_name>
      <phone>971 175000</phone>
      <email>antonia.sampolm@ssib.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesus San Miguel, Dr</last_name>
      <phone>948 296296</phone>
      <email>sanmiguel@unav.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Mª Arguiñano Pérez, Dr</last_name>
      <phone>848 429119</phone>
      <email>jm.arguinano.perez@cfnavarra.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Pontevedra</name>
      <address>
        <city>Pontevedra</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana María Dios Loureiro, Dr</last_name>
      <phone>986 800050</phone>
      <email>ana.maria.dios.loureiro@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Sabadell (Parc Taulí)</name>
      <address>
        <city>Sabadell</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Rámila Herrero, Dr</last_name>
      <phone>937 231010</phone>
      <email>MRamila@tauli.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M Victoria Mateos, Dr</last_name>
      <phone>923 291384</phone>
      <email>mvmateos@usal.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Donostia</name>
      <address>
        <city>San Sebastián</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maialen Sirvent Auzmendi, Dr</last_name>
      <phone>943 007000</phone>
      <email>MAIALEN.SIRVENTAUZMENDI@osakidetza.eus</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario Nuestra Señora de la Candelaria</name>
      <address>
        <city>Santa Cruz De Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Ríos, Dr</last_name>
      <phone>Pablo</phone>
      <email>pablo.riosrull@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo Martín, Dr</last_name>
      <phone>942 315321</phone>
      <email>guillermo.martin@scsalud.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago</name>
      <address>
        <city>Santiago De Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Sonia González Pérez, Dr</last_name>
      <phone>981 950 171</phone>
      <email>marta.sonia.gonzalez.perez@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General de Segovia</name>
      <address>
        <city>Segovia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aránzazu García Mateos, Dr</last_name>
      <phone>921 419671</phone>
      <email>aranzazugarciamateo@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Universitario Virgen de Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Estrella Carrillo, Dr</last_name>
      <phone>955 013277</phone>
      <email>estrellacarrillocruz@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Nuestra Señona de Valme</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Joan XXIII de Tarragona</name>
      <address>
        <city>Tarragona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josep Sarrá Escarré, Dr</last_name>
      <phone>977 295800</phone>
      <email>jsarra@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Teodoro Hernández García, Dr</last_name>
      <phone>922 678650</phone>
      <email>mthernan@ull.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Toledo (Virgen de la Salud)</name>
      <address>
        <city>Toledo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe Casado Montero, Dr</last_name>
      <phone>925 269243</phone>
      <email>lfcasadom@telefonica.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Isabel Teruel Casasus, Dr</last_name>
      <phone>961 973838</phone>
      <email>ateruelc@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Morales Meseguer</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Felipe de Arriba de la Fuente, Dr</last_name>
      <phone>968 360951</phone>
      <email>farriba@um.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic la Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Arnao Herraiz, Dr</last_name>
      <phone>96 1244192</phone>
      <email>arnao_mar@gva.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Peset Aleixandre</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier de la Rubia, Dr</last_name>
      <phone>963 862500</phone>
      <email>delarubia_jav@gva.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Vigo</name>
      <address>
        <city>Vigo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Margarita Martínez, Dr</last_name>
      <phone>986 217832</phone>
      <email>ana.margarita.martinez.castro@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Txagorritxu</name>
      <address>
        <city>Vitoria</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernesto Perez Persona, Dr</last_name>
      <phone>945 007171</phone>
      <email>ernesto.perezpersona@osakidetza.eus</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Palomera Bernal, Dr</last_name>
      <phone>976 765700</phone>
      <email>lpalomera@salud.aragon.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Delgado Beltrán, Dr</last_name>
      <phone>976 765500</phone>
      <email>pdelgadob@salud.aragon.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 13, 2018</study_first_submitted>
  <study_first_submitted_qc>November 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2018</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

